Literature DB >> 21188512

The quality of medical care, behavioral risk factors, and longevity growth.

Frank R Lichtenberg1.   

Abstract

The rate of increase of longevity has varied considerably across U.S. states since 1991. This paper examines the effect of the quality of medical care, behavioral risk factors (obesity, smoking, and AIDS incidence), and other variables (education, income, and health insurance coverage) on life expectancy and medical expenditure using longitudinal state-level data. We examine the effects of three different measures of the quality of medical care. The first is the average quality of diagnostic imaging procedures, defined as the fraction of procedures that are advanced procedures. The second is the average quality of practicing physicians, defined as the fraction of physicians that were trained at top-ranked medical schools. The third is the mean vintage (FDA approval year) of outpatient and inpatient prescription drugs. Life expectancy increased more rapidly in states where (1) the fraction of Medicare diagnostic imaging procedures that were advanced procedures increased more rapidly; (2) the vintage of self- and provider-administered drugs increased more rapidly; and (3) the quality of medical schools previously attended by physicians increased more rapidly. States with larger increases in the quality of diagnostic procedures, drugs, and physicians did not have larger increases in per capita medical expenditure. We perform several tests of the robustness of the life expectancy model. Controlling for per capita health expenditure (the "quantity" of healthcare), and eliminating the influence of infant mortality, has virtually no effect on the healthcare quality coefficients. Controlling for the adoption of an important nonmedical innovation also has little influence on the estimated effects of medical innovation adoption on life expectancy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21188512     DOI: 10.1007/s10754-010-9086-y

Source DB:  PubMed          Journal:  Int J Health Care Finance Econ        ISSN: 1389-6563


  9 in total

1.  Socioeconomic factors affecting the longevity of the Japanese population: a study for 1980 and 1985.

Authors:  E Uchida; S Araki; K Murata
Journal:  J Biosoc Sci       Date:  1992-10

2.  The impact of increased utilization of HIV drugs on longevity and medical expenditure: an assessment based on aggregate US time-series data.

Authors:  Frank R Lichtenberg
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2006-08       Impact factor: 2.217

Review 3.  The effect of access restrictions on the vintage of drugs used by Medicaid enrollees.

Authors:  Frank R Lichtenberg
Journal:  Am J Manag Care       Date:  2005-01       Impact factor: 2.229

4.  The gap gets bigger: changes in mortality and life expectancy, by education, 1981-2000.

Authors:  Ellen R Meara; Seth Richards; David M Cutler
Journal:  Health Aff (Millwood)       Date:  2008 Mar-Apr       Impact factor: 6.301

5.  Deaths: final data for 2006.

Authors:  Melonie Heron; Donna L Hoyert; Sherry L Murphy; Jiaquan Xu; Kenneth D Kochanek; Betzaida Tejada-Vera
Journal:  Natl Vital Stat Rep       Date:  2009-04-17

6.  Medical innovation duels cost containment.

Authors:  R A Rettig
Journal:  Health Aff (Millwood)       Date:  1994       Impact factor: 6.301

7.  Excess deaths associated with underweight, overweight, and obesity.

Authors:  Katherine M Flegal; Barry I Graubard; David F Williamson; Mitchell H Gail
Journal:  JAMA       Date:  2005-04-20       Impact factor: 56.272

8.  The effect of using newer drugs on admissions of elderly Americans to hospitals and nursing homes: state-level evidence from 1997 to 2003.

Authors:  Frank R Lichtenberg
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

9.  Eight Americas: investigating mortality disparities across races, counties, and race-counties in the United States.

Authors:  Christopher J L Murray; Sandeep C Kulkarni; Catherine Michaud; Niels Tomijima; Maria T Bulzacchelli; Terrell J Iandiorio; Majid Ezzati
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

  9 in total
  3 in total

1.  Contribution of pharmaceutical innovation to longevity growth in Germany and France, 2001-7.

Authors:  Frank R Lichtenberg
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

2.  Endogenous technological change in medicine and its impact on healthcare costs: evidence from the pharmaceutical market in Taiwan.

Authors:  Chee-Ruey Hsieh; Ya-Ming Liu; Chia-Lin Chang
Journal:  Eur J Health Econ       Date:  2011-12-27

3.  Trialling of an optimal health programme (OHP) across chronic disease.

Authors:  Chantal F Ski; David R Thompson; David J Castle
Journal:  Trials       Date:  2016-09-09       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.